Impel Neuropharma Archives - Medical Design Sourcing

Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation

Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand.

Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in adults received FDA approval in September 2021 and the company followed the regulatory nod with the pricing of a $45 million offering a week later.

Get the full story at our sister site, Drug Delivery Business News.

Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment

Impel NeuroPharma (NSDQ:IMPL) announced that it priced an underwritten public offering of common stock worth $45 million.

The offering includes 3 million shares of common stock priced to the public at $15 per share, with gross proceeds set to total $45 million before deducting underwriting discounts and commissions and other offering expenses payable by Impel NeuroPharma.

Get the full story at our sister site, Drug Delivery Business News.

FDA approves Impel NeuroPharma’s nasal spray for treating migraines

Impel NeuroPharma (NSDQ:IMPL) announced today that the FDA approved its Trudhesa nasal spray for treating migraine in adults.

Seattle-based Impel NeuroPharma plans to launch Trudhesa commercially early next month. The company’s shares took a massive hit, though, dropping -19.3% at $18.65 per share by market close and continuing to slide down -0.8% at $18.50 after hours today.

Get the full story at our sister site, Drug Delivery Business News.